Predictors of Clinical Outcomes of Deep Brain Stimulation in Parkinson's Disease
A Prospective Observational Study for the Predictors of Clinical Outcomes of Deep Brain Stimulation in Parkinson's Disease
1 other identifier
observational
30
1 country
1
Brief Summary
The goal of this observational study is to identify factors in blood that are associated with response to deep brain stimulation (DBS) surgery in patients with Parkinson's disease. The main questions it aims to answer are:
- 1.What factors in blood (proteins and RNA) are associated with good vs poor response to DBS?
- 2.Are these factors able to predict response to DBS?
- 3.How do these factors change before and after DBS?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Feb 2026
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 22, 2026
CompletedFirst Posted
Study publicly available on registry
January 29, 2026
CompletedStudy Start
First participant enrolled
February 5, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2036
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 1, 2038
February 24, 2026
February 1, 2026
10 years
January 22, 2026
February 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Blood proteomic profile
Plasma proteins measured using high-throughput ultra-sensitive proteomics platform
From pre-operative to 5 years post-operative
Blood transcriptomic profile
Bulk RNA-sequencing of blood cells
From pre-operative to 5 years post-operative
Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Rating scale that measures non-motor experiences of daily living (part I), motor experiences of daily living (part II), motor function via physical examination (part III), and motor complications (part IV) Higher scores indicate a worse outcome Range: Part I: 0-52 Part II: 0-52 Part III: 0-132 Part IV: 0-24
From pre-operative to 5 years post-operative
Hoehn and Yahr (H&Y) stage
Staging of overall functional disability in Parkinson's disease Higher score indicates a worse outcome Range: 0-5 Stage 0: No signs of disease Stage 1: Unilateral disease Stage 1.5: Unilateral plus axial involvement Stage 2: Bilateral disease without impairment of balance Stage 2.5: Mild bilateral disease with recovery on pull test Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent Stage 4: Severe disability; still able to walk / stand unassisted Stage 5: Wheelchair bound or bedridden unless aided
From pre-operative to 5 years post-operative
Secondary Outcomes (6)
Montreal Cognitive Assessment (MoCA)
From pre-operative to 5 years post-operative
Non-Motor Symptoms Scale (NMSS)
From pre-operative to 5 years post-operative
Parkinson's Disease Sleep Scale - 2 (PDSS-2)
From pre-operative to 5 years post-operative
Parkinson's Disease Questionnaire - 39 (PDQ-39)
From pre-operative to 5 years post-operative
Depression, Anxiety, and Stress Scale - 21 (DASS-21)
From pre-operative to 5 years post-operative
- +1 more secondary outcomes
Study Arms (1)
Treatment
Parkinson's disease patients who have received deep brain stimulation
Interventions
Eligibility Criteria
Parkinson's disease patients of the movement disorder clinic at Queen Elizabeth Hospital Hong Kong
You may qualify if:
- Diagnosis of "Clinically Established PD" as defined by the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (MDS-PD criteria)
- Referred for DBS according to standard local clinical guidelines 2a. Significant motor complications despite optimized pharmacological treatment 2ai. UPDRS motor score \>30/108 in the off-medication state 2aii. Hoehn and Yahr staging \>2.5/5 in the off-medication state 2b. Dopamine responsive 2bi. \>33% improvement in UPDRS motor score after levodopa administration 2c. Age ≤75 years 2d. No contraindication to surgery or other significant comorbidity with limited life expectancy 2e. No significant psychiatric problems or cognitive impairment 2f. No structural lesions or features suggestive of atypical parkinsonism or other mimickers of idiopathic PD on neuroimaging
You may not qualify if:
- Unwilling to undergo blood sampling for study purposes
- Evidence of Parkinsonism due to heavy metal exposure
- History of neurodevelopmental disorder, neurodegenerative disease other than PD, CNS infection, neuroinflammatory disease (e.g. multiple sclerosis, CNS lupus), malignancy within the last 10 years, cerebrovascular accident, HIV infection, systemic autoimmune disease, alcohol dependence or other substance use
- Unable to pass DBS pre-operative assessment or unwilling to undergo DBS
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Hong Kong University of Science and Technology
Hong Kong, Hong Kong
Biospecimen
Blood, brain tissue
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nancy Ip
The Hong Kong University of Science and Technology
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant scientific officer
Study Record Dates
First Submitted
January 22, 2026
First Posted
January 29, 2026
Study Start
February 5, 2026
Primary Completion (Estimated)
February 1, 2036
Study Completion (Estimated)
February 1, 2038
Last Updated
February 24, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share